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Summary
Objective: Both matrix metalloprotease (MMP) activity and cathepsin K (CK) activity have been implicated in cartilage turnover. We investi-
gated the relative contribution of MMP activity and CK activity in cartilage degradation using ex vivo and in vivo models.
Methods: Bovine articular cartilage explants were stimulated with oncostatin M (OSM) 10 ng/ml and tumor necrosis factor-a (TNF-a) 20 ng/ml
in the presence or absence of the broad-spectrum MMP inhibitor GM6001 and the cysteine protease inhibitor, E64. Cartilage degradation was
evaluated in the conditioned medium by glycosaminoglycans (GAG), hydroxyproline, and cross-linked C-telopeptide fragments of type II col-
lagen (CTX-II), which were compared to immunohistochemical evaluations of proteoglycans and CTX-II. We assessed MMP expression by
gelatine zymography and CK expression by immunohistochemistry. In vivo, CTX-II release was measured from CK-deﬁcient mice.
Results: OSM and TNF-a combined induced signiﬁcant (P< 0.01) increase in cartilage degradation products measured by hydroxyproline and
CTX-II compared to vehicle control. The cytokines potently induced MMP expression, assessed by zymography, and CK expression inves-
tigated by immunohistochemistry. Inhibition of MMP activity completely abrogated hydroxyproline and CTX-II release (P< 0.01) and GAG re-
lease (P< 0.05). In contrast, E64 resulted in increased CTX-II release by 100% (P< 0.05) and inhibited GAG release by 30%. Up-regulation
of CTX-II fragments was conﬁrmed in vivo in CK null mice.
Conclusion: Inhibition of MMP activity reduced both proteoglycan loss and type II collagen degradation. In contrast, inhibition of cysteine pro-
teases resulted in an increase rather than a decrease in MMP derived fragments of collagen type II degradation, CTX-II, suggesting altered
collagen metabolism.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a major cause of functional impair-
ment and disability among the elderly1, however, current
therapies predominantly alleviate symptoms rather than
protect cartilage. Better understanding of the mechanisms
of cartilage degradation is essential for identifying targets,
which promise effective prevention and treatment. Protease
activity has been a target for intervention in OA to reduce
degradation of cartilage2. However, compensation by other
proteases has been suggested to attenuate efﬁcacy3, which
potentially could lead to deleterious side effects. This war-
rants further investigation of the interrelationships between
various families of proteases.
The major part of cartilage is composed of collagen type II
(60e70% of dry weight) and proteoglycans (10% of dry
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Received 20 June 2005; revision accepted 31 January 2006.73weight) of which aggrecan is the most abundant4. The key
mediators of cartilage degradation in vivo and in vitro include
the matrix metalloproteases (MMPs) and members of the
closely related family of a disintegrin and metalloproteases
(ADAMs) with thrombospondin motifs (ADAM-TS)5,6. Aggre-
can is degraded both by MMPs and ADAM-TSs, in particular
ADAM-TS4 andADAM-TS57e11, whereas collagen type II for
the major part is degraded by various MMPs12,13. The action
of theseendopeptidases in articular cartilage results in the re-
lease of various extracellular fragments from the articularma-
trix, of which aggrecan and collagen type II are primarily
investigated14,15. However, recent evidence has suggested
a role of the cysteine protease, cathepsin K (CK), in addition
to the well-established role of MMPs in cartilage degrada-
tion16,17. CK was shown to degrade aggrecan both at acidic
and neutral pH as well as collagen type II at acidic pH18e22
and to a lower extent at neutral pH20.With these observations
in mind, CK was speculated to be a pharmaceutical target for
degenerative cartilage diseases19,20,23.
Several studies have provided evidence that oncostatin
M (OSM) and tumor necrosis factor-a (TNF-a) are inducers
of cartilage degradation in vitro and in vivo13. OSM is8
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ously been shown to have synergism with a number of
pro-inﬂammatory cytokines in promoting collagen degrada-
tion13,24e26. Recently, OSM and TNF-a were shown to be
potent and synergistic inducers of cartilage degradation,
by induction of MMP-1, 3, and 1313.
We wanted to investigate the proteases involved in
cartilage degradation and to investigate in more detail
the proteolytic machinery responsible for the cartilage
catabolic activity in response to OSM and TNF-a. The
aim of the present study was to use an ex vivo articular
cartilage culture system to investigate the relative contribu-
tion of MMP activity and cysteine proteinases in cartilage
turnover. We investigated collagen type II turnover by
measuring hydroxyproline and neoepitopes from collagen
type II degradation (CTX-II)27e29, and proteoglycan turn-
over by toluidine blue staining and measurements of
glycosaminoglycan (GAG) release in the conditioned
medium.
Materials and methods
REAGENTS
The reagents applied were of analytical grade. The cul-
ture medium comprised Dulbecco’s Modiﬁed Eagle Medium
(D-MEM) with penicillin and streptomycin, all from Life
Technologies, US. Human recombinant OSM was obtained
from SigmaeAldrich, UK, and human recombinant TNF-a,
from R&D systems, UK. The broad-spectrum ADAM/MMP
inhibitor30e32 N-[2(R)-2-(hydroxamido carbonylmethyl)-4-
methylypentanoyl]-L-tryptophane methylamide, GM6001,
was supplied from AMS Scientiﬁc, US, the cysteine prote-
ase inhibitor, E64, and the synthetic membrane permeable
analogue, E64d, were from SigmaeAldrich, UK.
TISSUE PREPARATION
Bovine articular cartilage explants were carefully har-
vested by scalpelling the outermost layer of articular carti-
lage without adherent calciﬁed cartilage from bovine heifer
stiﬂe joints between 1 and 1.5 years. The cartilage explants
(16 4 mg) were washed three times in PBS and placed in
96 well plates and incubated at 37(C, 5% CO2 with shaking
at 50 rpm, and cultured under serum-free conditions in
200 mL D-MEM containing cytokines, as speciﬁed in the ﬁg-
ure legends. As control, articular cartilage explants and
metabolic inactivated explants were cultured in D-MEM. In
order to deactivate the metabolism of the articular cartilage
explants used for ‘‘metabolic inactive’’ treatment, the ex-
plants were placed in cryotubes (Nunc, DK), then frozen
in liquid N2 and thawed at 37(C in water-bath for three re-
peated freeze-thaw cycles. The conditioned medium was
replaced every 3rd day with freshly prepared medium.
The supernatants were stored at 20(C until further
analysis.
BREEDING OF MICE
CK-deﬁcient mice were generated as previously
described33 and outcrossed to the C57BL/6 background.
F2-generation from intercrossing with normal CK genotype
was used for the experiments. Thirteen CK/ and
17 CKþ/ mice were sacriﬁced at week 10 after birth
and blood samples were collected for investigation of
CTX-II levels.GENOTYPING OF MICE
Tail tips of each investigated mouse of F2-generation
were taken and digested in lysis buffer overnight to deter-
mine the genotype33. The disruption of the CK-gene was
tested by polymerase chain reaction (PCR) using primer
A ‘‘50-GCC-ACA-CCC-ACA-CCC-TAG-AAG-30’’ and primer
B ‘‘50-ACA-AGT-GTA-CAT-TCC-CGT-ACC-30’’. Mice, that
were heterozygous for CK, displayed two speciﬁc PCR
bands at 1.6 kb and 0.4 kb. CK-deﬁcient mice only showed
the PCR band at 1.6 kb.
MEASUREMENTS OF HYDROXYPROLINE
Collagen degradation was evaluated by measuring the
content of hydroxyproline in the explants’ supernatants us-
ing a modiﬁed version of Podenphant et al.34. Brieﬂy, 10 mL
sample was diluted ﬁve times in 7.5 M HCl and hydrolyzed
20 h at 110(C, and the liquid was evaporated overnight at
50(C. The precipitate was dissolved in 250 mL isopropanol
milli Q water solution (2:1). Then 10 mL solution was mixed
with 20 mL isopropanol and 10 mL reagent A (reagent A (1:4)
of 24 M chloramine T and 1 M Na-acetate, 0.33 M Na3 cit-
rate, 0.07 M citric acid dissolved in isopropanol). The mix-
ture was incubated 4 1 min at room temperature and
added 130 mL of reagent B (reagent B (3:13) of 4.5 M 4-
dimethylamino-benzaldehyde dissolved in 60% perchloric
acid and isopropanol). The samples were incubated
25 min at 60(C and absorbance was read at 558 nm on
an ELISA-reader. Standards were prepared from 1-hydroxy-
proline diluted in 1 mM HCl. Bone samples digested with
collagenase were used as controls.
MEASUREMENTS OF GAG
For detection of sulfated glycosaminoglycans (sGAG),
the quantitative dye-binding assay for in vitro analysis of
GAG release was used according to the manufacturer’s in-
structions (Wieslab, S). In short, samples, standards, blank,
and control were added to guanidineeHCl and incubated
for 15 min, 0.3% H2SO4 and 0.75% Triton X-100 was added
and the samples were incubated for 15 min. Finally Alcian
blue working solution was added followed by 15 min incuba-
tion. The samples and standards were centrifuged for an-
other 15 min and the pellets were dissolved in Dimethyl
Sulfoxid (DMSO), and the solutions were centrifuged again
at 12,000g and then dissolved in 4 M guanidineeHCl,
33.3% 1-propanol and 0.25% Triton X-100. The absorbance
was read at 620 nm on an ELISA-reader.
BIOCHEMICAL MARKERS OF CARTILAGE DEGRADATION
Conditioned medium
C-telopeptide fragments of type II collagenweremeasured
in the pre-clinical (PC) CartiLaps ELISA (Nordic Bioscience
Diagnostics, DK); an enzyme-linked immunosorbent assay
(ELISA) based on mouse monoclonal antibody targeting
a six amino acid epitope (EKGPDP) at the C-terminal
telopeptide of collagen type II. The PC CartiLaps ELISA is
a modiﬁcation of the Urine CartiLaps ELISA27,35 optimized
for the detection of CTX-II fragments in animal urine and
culture medium. This assay has no signiﬁcant cross-reactiv-
ity with type I collagenC-telopeptides27,35. The detection limit
of the assay is 0.75 ng/ml and the intra- and inter-assay
coefﬁcients of variation (CV) in the PC CartiLaps assay are
lower than 6%.
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Serum PC CTX-II sandwich ELISA was used for the esti-
mation of cartilage degradation in serum samples obtained
from rodents (Nordic Bioscience Diagnostics, DK). The as-
say is based on highly speciﬁc monoclonal antibodies
raised against the amino acid sequence EKGPDP located
at the C-terminal telopeptide of collagen type II. The lowest
detection limit is 1.1 pg/mL and the intra- and inter-assay
CV is below 8.0%.
ENZYMATIC ASSAYS FOR COLLAGEN TYPE II DEGRADATION
All reactions were carried out in 0.5 mL of MMP buffer
(50 mM TriseHCl buffer (pH 7.5), 10 mM CaCl2, and
1 mM ZnCl2). Bovine articular cartilage (2e3 mg) was sub-
merged in liquid nitrogen and defrosted three times. Then
the cartilage was washed three times in MMP buffer.
MMP-9 and MMP-13 (R&D systems, US) were APMA (p-
aminophenylmercuric acetate) activated by incubation with
1 mM APMA for 2 h at 37(C. After activation, 10 mL of en-
zyme suspension was added to 0.490 mL aliquots of bovine
cartilage explants resulting in a ﬁnal concentration of 20 nM
MMP-9 or MMP-13. Incubations were performed in tripli-
cates for 24 h at 37(C under gentle agitation. The reaction
was stopped by adding 10 mL of 10 mM GM6001 (AMS Sci-
entiﬁc, US). The mixture was centrifuged for 20 min at
1500g at 4(C, and the supernatants were kept frozen at
80(C before measurement for CTX-II. Cartilage alone,
cartilageþMMP, MMP buffer alone (as negative control),
and cartilageþMMPþGM6001 were measured in the Car-
tiLaps ELISA (Nordic Bioscience Diagnostics, DK).
ZYMOGRAPHY
MMP expression and activity were determined by gelati-
nase zymography using 0.5 mg/mL of gelatine (Sigmae
Aldrich, UK) as a substrate in 7.5% SDS-polyacrylamide
gels. A volumeof 5 mLof culture supernatant, rainbowmarker
(Amersham, US), and gelatinase zymography standards for
both MMP-2 and MMP-9 (Chemicon, US) and MMP-2 alone
(Amersham, US) were loaded on the zymography gels, and
the proteins were separated. After electrophoresis the gels
were washed three times with 2.5% Triton X-100 in water
and then incubated overnight at 37(C in 0.1% Triton X-100,
5 mM CaCl2, 1 mM ZnCl2, 3 mM NaN3, 50 mM Tris pH 7.4
in a closed container. Gels were stained for 30 min with
0.25%Coomassie R-250 (SigmaeAldrich, UK) in 10%acetic
acid and 45% methanol and destained for 30 min with 20%
acetic acid, 20% methanol, 17% ethanol, 0.6% diethylether.
Gels were dried and scanned for documentation.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
The bovine articular cartilage explants were ﬁxed in 3.7%
formaldehyde in PBS pH 7, parafﬁn embedded, and subse-
quently sectioned into 5 mm sections. The proteoglycans
were stained by toluidine blue after deparafﬁnization and re-
hydration. Immunohistochemistry was performed using
monoclonal mouse antibodies against CK (Chemicon, US)
and CTX-II (Nordic Bioscience Diagnostics, DK). The sec-
tions used for immunolocalization of CK were pre-treated
in 10 mM Tris and 0.25 mM Ethylenediaminetetraacetic
acid (EDTA), pH 9 overnight to enhance epitope availability.
CTX-II immunolocalization was performed without pre-treat-
ment of the sections. The cartilage sections were blocked
for non-speciﬁc binding in TBS containing 0.5% casein(TBS/CAS) and subsequently incubated with mouse mono-
clonal CTX-II antibody diluted in TBS/CAS. Peroxidase
labeled mouse Envision (DAKOcytomation, DK) was used
as secondary antibody. Finally, the immunoreactivity was
visualized by liquid DABþ substrate chromogen solution
(3,30-diaminobenzidine chromogen solution; Sigmae
Aldrich, UK) followed by rinsing of the slides in tap water.
As control, the CartiLaps-peptide (Pepceuticals Ltd., UK)
was used in 50-M excess to evaluate the speciﬁcity of the
CTX-II staining. A matching IgG1k was used as negative
control parallel to the anti-CK. The sections were counter-
stained with Ehrlich’s hematoxylin. Digital histographs
were taken using an Olympus BX-60 microscope and an
Olympus C5050 zoom camera.
STATISTICS
All graphs show one representative experiment of at least
four, each with at least four individual replications. Mean
values and S.E.M. were calculated using GraphPad Prism,
and compared by the Student’s two-tailed unpaired t-test
of statistical signiﬁcance assuming normal distribution
where four replications were used. The asterisks indicate
the signiﬁcance levels (*P< 0.05, **P< 0.01, ***P< 0.001).
Results
COLLAGEN TYPE II DEGRADATION IS INDUCED BY OSM
AND TNF-a
Combined stimulation of bovine articular cartilage explants
by OSM and TNF-a evoked marked increases in cartilage
degradation. The conditioningmediumwas fully replaced ev-
ery3rdday, freshlypreparedwithcytokines.TNF-a (16 ng/ml)
in presence of OSM (10 ng/ml) time-dependently induced
cartilage degradation as measured by CTX-II [Fig. 1(A)].
TNF-a concentration-dependently increased the release
of CTX-II compared to the controls [Fig. 1(B)], and the high-
est concentration of TNF-a (64 ng/ml) gave more than
1000-fold increase in CTX-II release. Prolonged exposure
of explants to this combination of OSM and TNF-a led to
complete digestion of the explants after 31 days of culture
(data not shown). The magnitude of increase in CTX-II re-
lease measured after 28 days of incubation from OSM
(10 ng/ml) and TNF-a (16 ng/ml) was 500-fold compared
to untreated vehicle controls and 1000-fold compared to
metabolically inactivated cartilage explants [Fig. 1(B)]. The
cytokines alone in the tested concentrations did not induce
cartilage degradation as measured by CTX-II release even
after prolonged culture (data not shown). Thus, a synergistic
effect of the cytokines was observed from 10 ng/ml OSM
and 4 ng/ml TNF-a. From these experiments, the culture
conditions were decided to be 10 ng/ml OSM and 20 ng/
ml TNF-a, which allow investigation of both inhibitory and
stimulatory effects on cartilage turnover.
OSM AND TNF-a INDUCE MMP EXPRESSION
To investigate the proteases responsible for the degrada-
tion of articular cartilage, we investigated the expression of
gelatinases by gelatine zymography36,37. Conditioned me-
dium from six time-points, control and the corresponding
cytokine-stimulated explants were loaded on the gels. As
shown in Fig. 2, we found a low expression of gelatinases
in the absence of cytokines. However, in the presence of
OSM and TNF-a we identiﬁed high expression of bands cor-
responding to MMP-9 and MMP-2, as determined by their
741Osteoarthritis and Cartilage Vol. 14, No. 8Fig. 1. TNF-a induces time and concentration-dependent cartilage degradation. Bovine articular cartilage explants were cultured under serum-
free conditions with a combination of the cytokines OSM and TNF-a for 23 days. Every 3rd day the conditioning medium was fully replaced
with fresh medium with or without cytokines as speciﬁed under the ﬁgures. (A) CTX-II release from days 3, 9, 16, and 23 from articular cartilage
explants cultured in the presence of OSM 10 ng/ml and TNF-a 16 ng/ml. (B) CTX-II release in the absence or presence of increasing concen-
trations of TNF-a at day 28 of culture. The CTX-II release is adjusted for the amount of cultured cartilage. Each bar represents the mean
valueþ S.E.M. from four individual wells. The asterisks indicate signiﬁcant differences (*P< 0.05, **P< 0.01, ***P< 0.001).corresponding standards, and to a lower extent other gelat-
inases as well. At late time-points, day 13 and day 17,
a band appeared with an apparent molecular weight of
40 kDa corresponding to active MMP-13 activity, as previ-
ously observed by zymography38. In parallel, as a control
for MMP activity, the gelatine zymography gels were incu-
bated with the general MMP inhibitor GM6001 (50 mM)39,
and the gelatinase activity was completely abrogated
(data not shown).
MMP-9 AND MMP-13 DEGRADE COLLAGEN TYPE II RESULTING
IN CTX-II EPITOPES
Previous investigations have strongly implicated MMP-9
and MMP-13 in several cartilage pathologies40, and the
present studies show that in particular MMP-9 activity was
induced in the articular cartilage cultures stimulated with
OSM and TNF-a to induce cartilage degradation. Thus,
we investigated the ability of MMP-9 and MMP-13 to gener-
ate CTX-II epitope. As presented in Fig. 3, incubation of na-
tive articular cartilage with 20 nM of MMP-9 or MMP-13
resulted in a 100-fold increase in collagen degradation, as
measured by CTX-II. GM6001 was used as control andcompletely abrogated collagen type II degradation, as mea-
sured by CTX-II, demonstrating that this collagen degrada-
tion was MMP speciﬁc.
OSM AND TNF-a INDUCE CK EXPRESSION
To further investigate the protease machinery responsible
for the generation of the CTX-II epitope, we investigated CK
expression in both the OSM and TNF-a stimulated cartilage
explants and the control articular cartilage explants, using
immunohistochemistry. In the absence of OSM and TNF-
a we were unable to detect CK expression [Fig. 4(A)]. How-
ever, in the presence of OSM and TNF-a high immunoreac-
tivity of CK was detected [Fig. 4(B)].
OSM AND TNF-a INDUCED GAG RELEASE IS STRONGLY
ATTENUATED BY INHIBITION OF MMP ACTIVITY AND TO
A LESSER EXTENT BY INHIBITION OF CYSTEINE PROTEASE
ACTIVITY
To investigate the role of MMPs and cysteine proteases
in proteoglycan turnover in the articular cartilage explants’
model we measured GAG release induced by OSM andFig. 2. OSM and TNF-a induce MMP-2 and MMP-9 expression. Gelatinase activity was investigated by zymography in conditioned medium
from bovine articular cartilage explants. Standards for MMP-9þMMP-2 and MMP-2 alone was used. The adjacent lanes, from either 3, 6, 8,
10, 13, or 17 days of culture are conditioned medium without cytokines, and the corresponding OSM 10 ng/ml and TNF-a 20 ng/ml stimulated
cartilage. MMP-2 and MMP-9 activities increased over time in conditioned medium from bovine articular cartilage explants cultured with OSM
10 ng/ml and TNF-a 20 ng/ml. Each lane represents individual wells.
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we used the MMP inhibitor GM6001 and the cysteine prote-
ase inhibitor E64 [Fig. 5(A,B)]. OSM and TNF-a induced
a more than twofold signiﬁcant (P< 0.01 and P< 0.001) in-
crease in GAG release both at days 2 and 6, compared to
vehicle treated control as seen in Fig. 5(A and B), respec-
tively. Inhibition of MMP activity by 10 mM GM6001 inhibited
the OSM and TNF-a induced proteoglycan release by ap-
proximately 70% [Fig. 5(A,B)]. The cysteine protease inhib-
itor, E64 (40 mM), inhibited the GAG release by 30e40%,
albeit not signiﬁcant. Similar results were obtained by the
membrane permeable E64d (data not shown). The potency
of E64 was conﬁrmed in human osteoclast cultures accord-
ing to Ref.41, and was found to completely abrogate CK ac-
tivity at 40 mM, as measured by the release of collagen
fragments from bone slices (data not shown). These results
might indicate the relative importance of the different
Fig. 3. MMP-9 and MMP-13 induce CTX-II release in vitro. Articular
cartilage was incubated with or without MMP-9 and MMP-13 in
MMP buffer and the general MMP inhibitor, GM6001, as control.
The suspensions were centrifuged and cross-linked neoepitopes
from type II collagen (CTX-II) were measured from the superna-
tants. The asterisks indicate signiﬁcant differences (***P< 0.001).proteases in cartilage degradation. The cell viability was
measured by AlamarBlue, as previously described for
three-dimensional cell cultures39, in order to ensure that
the decrease in cartilage degradation was not due to cell
toxic effects of E64 and GM6001. None of the inhibitors
were found to be cell toxic (data not shown).
OSM AND TNF-a INDUCED COLLAGEN TYPE II DEGRADATION
IS ABROGATED BY INHIBITION OF MMP ACTIVITY, BUT NOT CK
ACTIVITY
As both CK and members of the MMP family are induced
by OSM and TNF-a stimulation (Figs. 2 and 4), we investi-
gated the relative contribution of these proteases to the col-
lagen type II degradation investigated by hydroxyproline
and CTX-II release in the conditioned medium by the use
of the general MMP inhibitor, GM6001, and the cysteine
protease inhibitor, E64. The generation of CTX-II epitopes
over days and the accumulated data is seen from
Fig. 6(A) and the accumulated hydroxyproline release
from Fig. 6(B). OSM and TNF-a induced a more than
100-fold increase in cartilage degradation compared to ve-
hicle control as investigated by the measurement of CTX-
II fragments in the conditioned medium. Without OSM and
TNF-a cartilage degradation was absent, and comparable
to metabolic inactive cartilage. This potent induction of car-
tilage degradation was completely abrogated by inhibition of
MMP activity by GM6001. In contrast, inhibition of cysteine
protease activity by E64 resulted in a signiﬁcant (P< 0.05)
and more than 100% increase in CTX-II release and small
but not signiﬁcant increase in hydroxyproline release. Sim-
ilar results were obtained with the membrane permeable in-
hibitor, E64d, an analogue to E64 (data not shown). E64 did
not induce collagen type II degradation in cartilage explants
without cytokine stimulation (data not shown).
INHIBITION OF MMP ACTIVITY, BUT NOT CK ACTIVITY,
ABROGATES PROTEOGLYCAN LOSS EX VIVO
To further investigate the role of MMPs and the cysteine
proteases in proteoglycan and collagen turnover in theFig. 4. CK expression is found in OSM and TNF-a activated cartilage. Immunohistochemical analysis of CK in bovine articular cartilage ex-
plants. Mouse monoclonal antibody against human CK was used to localize CK in sections from articular cartilage explants. (A) Articular car-
tilage explants cultured without cytokines. (B) Articular cartilage explants cultured in the presence of OSM 10 ng/ml and TNF-a 20 ng/ml.
Tissue sections were counterstained with Ehrlich’s hematoxylin.
743Osteoarthritis and Cartilage Vol. 14, No. 8Fig. 5. OSM and TNF-a induced sGAG release was strongly attenuated by inhibition of matrix metalloproteinase (MMP) activity and to a lesser
extent by inhibition of cysteine protease activity. Cartilage degradation was induced in bovine articular cartilage explants stimulated with the
cytokines OSM 10 ng/ml and TNF-a 20 ng/ml. The conditioned medium was replaced every 3rd day and the quantitative release of sGAG was
measured. (A) Represent the sGAG release after 2 days and (B) the sGAG release after 6 days of culture. Each bar represents the mean
valueþ S.E.M. from at least four individual wells, adjusted for the amount of cultured cartilage. GM6001, MMP activity inhibitor; E64, cysteine
proteinase inhibitor. The asterisks indicate signiﬁcant differences (*P< 0.05, **P< 0.01, ***P< 0.001).articular explants’ model we assessed proteoglycan content
by histology using toluidine blue staining and CTX-II by using
immunohistochemical localization of the CTX-II neoepitope.
As presented in the lower panel of Fig. 7 we found very low or
absent CTX-II staining in the absence of OSM and TNF-a,
which correlate to the presented CTX-II measurements in
the conditioned medium shown in Figs. 1(B) and 6(B).
OSM and TNF-a stimulated cartilage showed immunolocal-
ization of CTX-II epitope, which is in alignment with the
CTX-II measurements. Loss of proteoglycanswas visualized
by toluidine blue staining (upper panel of Fig. 7) in the extra-
cellular matrix. In line with the measurement of CTX-II in the
conditioned medium shown in Fig. 5, inhibition of MMP activ-
ity by GM6001 abrogated both proteoglycan loss and colla-
gen type II degradation. In contrast, inhibition of CK activity
by the cysteine protease inhibitor, E64, only to aminor extent
attenuated the loss of proteoglycans and did not neutralize
generation of the CTX-II neoepitope.COLLAGEN TYPE II FRAGMENTS ARE INCREASED
IN CK-DEFICIENT MICE
The ex vivo experiments demonstrated signiﬁcantly ele-
vated CTX-II levels in the absence of CK activity. To further
investigate the speciﬁc loss of CK activity on generation of
CTX-II epitopes in vivo, we used serum from 10-week-old
mice of either CK-deﬁcient mice33 or control littermates.
Measurements of CTX-II levels, showed 40% signiﬁcant
(P< 0.01) increase in CK null mice compared to wild type
control, as shown in Fig. 8.
Discussion
We have investigated the relative contribution of MMP
and cysteine protease activity in cartilage degradation.
We demonstrated that stimulation of articular cartilage
explants by OSM and TNF-a resulted in time- andFig. 6. Collagen degradation is mediated by MMPs, and not cysteine proteases. Bovine articular cartilage explants were cultured under serum-
free conditions in the presence of either vehicle or a combination of the cytokines OSM 10 ng/ml and TNF-a 20 ng/ml. The conditioned medium
was replaced every 3rd day and the CTX-II release (A) and the hydroxyproline (OHpr) release (B) were accumulated from day 3 to day 27. The
CTX-II and the hydroxyproline release were adjusted for the amount of cultured cartilage. Each bar represents the mean valueþ S.E.M. from
four individual wells. GM6001, MMP activity inhibitor; E64, cysteine proteinase inhibitor. The asterisks indicate signiﬁcant differences
(*P< 0.05, ***P< 0.001).
744 B. C. Sondergaard et al.: Relative contribution of MMP and cysteine protease activitiesFig. 7. Immunohistochemical localization of CTX-II fragments generated by MMPs. Bovine articular cartilage explants were cultured under
serum-free conditions with or without a combination of OSMþ TNF-a, and protease inhibitors where indicated; the general MMP inhibitor
GM6001 and cysteine protease inhibitor E64. At the last day in culture, day 23, the explants were ﬁxed in formaldehyde, parafﬁn embedded
and sectioned. The upper panel shows proteoglycan staining by toluidine blue, and the lower panel shows immunohistochemical detection of
collagen type II degradation, with a mouse monoclonal antibody against cross-linked C-telopeptide fragments of type II collagen (CTX-II). The
tissue sections were counterstained with Ehrlich’s hematoxylin.concentration-dependent cartilage degradation, which was
dependent on MMPs and not cysteine protease activity. In
addition, we present data indicating that in the absence of
CK, or by inhibition of cysteine protease activity, chondro-
cyte mediated degradation of the extracellular matrix shifts
to a more MMP like phenotype, resulting in more MMP gen-
erated fragments of collagen type II.
Stimulation with OSMþ TNF-a resulted in proteoglycan
loss in the initial culture period until day 9, followed by colla-
gen type II degradation starting from day 14. OSM and TNF-
a strongly induced CK expression and MMP expression, in
Fig. 8. In vivo loss of CK activity leads to increased CTX-II levels.
Serum CTX-II measurements were performed on either 10-week-
old CK heterozygous or null mutation mice. A total number of 30
mice were used to investigate CK-deﬁcient (CK/) in comparison
to CK-heterozygous mice (CKþ/) week 10 after birth: CKþ/
(n¼ 13) and CK/ (n¼ 17). The asterisks indicate signiﬁcant
differences (**P< 0.01).particular MMP-2 and MMP-9. Inhibition of MMPs by the
general MMP inhibitor, GM6001, neutralized the cytokine-
stimulated degradation of proteoglycans (GAG) and colla-
gen type II, as measured by hydroxyproline and CTX-II,
whereas inhibition of cysteine proteases by E64 and E64d
did not restrain the degradation of articular cartilage.
We demonstrated that MMP-9 and MMP-13, which have
been implicated in various cartilage pathologies42, were
able to generate CTX-II fragments, and that MMP-13 was
more potent than MMP-9 based on equivalent molar con-
centrations. Gelatinase zymography was used to identify
MMP activity from cytokine-stimulated explants, in which
primarily MMP-2 and MMP-9 were detected. After pro-
longed culture a band of approximately 40 kDa was de-
tected that corresponds to the molecular weight of active
MMP-1338, which may be further investigated by casein
zymography43. MMP-13 is a well-known triple helical prote-
ase and was able to generate the CTX-II neoepitope that
demands both a C- and N-terminal cleavage to release
the peptide from the matrix. Generation of the EKGPDP
(CTX-II) neoepitope from the C-terminal part of the collagen
type II telopeptide is well described and generated by
MMPs, which is demonstrated by the fact that the EKGPDP
is a prerequisite for the interaction of the antibody, as intact
collagen type II does not cross-react27,44. In addition, from
these experiments it can be concluded that not only the
triple-collagenase MMP-13 but also the gelatinase MMP-9
resulted in CTX-II generation, thus collagen metabolism
seems not to be restricted to triple-collagenase enzymes.
More research on the exact composition of the N-terminal
fragment is needed in order to further understand the colla-
gen type II metabolism of the chondrocytes, as multiple
protease sites are found upstream in collagen type II that
may allow the release of the CTX-II fragment.
We found that inhibition of MMPs completely abrogated
collagen type II degradation, as measured by hydroxyproline
745Osteoarthritis and Cartilage Vol. 14, No. 8and CTX-II release, and restored proteoglycan loss from the
articular cartilage explants to near control levels. Several
MMPs have been shown to cleave aggrecan45e47, albeit
ADAM-TS4 and 5 are the most important in situ mediators
of aggrecan degradation8,9,48. Presently, only MMPs have
been identiﬁed to cleave collagen type II, however, the
broad-spectrum MMP inhibitor GM600139 may indeed target
various ADAM-TS. Tortorella et al.49, have previously de-
scribed that ADAM-TS4 and 5 were unable to cleave colla-
gen type II, and future studies are required to address the
ability of ADAM-TS and MMPs to generate the CTX-II
epitope.
Inhibition of cysteine protease activity by E64 and E64d in
OSM and TNF-a stimulated cartilage resulted in a small de-
crease in proteoglycan degradation. Cysteine proteases
have been shown to be able to degrade aggrecan20,50, which
suggests a minor role of these proteases in cartilage turn-
over under diseased conditions. Inhibition of cysteine prote-
ase activity in cytokine-stimulated cartilage explants did not
attenuate collagen type II degradation, evaluated by hydroxy-
proline, CTX-II release, and immunohistochemistry. Interest-
ingly, inhibition of cysteine proteases signiﬁcantly increased
the CTX-II levels suggesting altered collagen type II metab-
olism, which may include compensatory mechanisms of
other collagenases in the absence of CK activity. These ﬁnd-
ings were conﬁrmed in the CK null mutation mice that dis-
played signiﬁcantly increased serum CTX-II levels. This is
in agreement with themRNA analysis of the CK null mutation
mice, which showed a 300% up-regulation of MMP-13 ex-
pression and a 50% up-regulation of MMP-9 expression3.
These biochemical studies indicate that CK-deﬁcient mice
may suffer from early arthritis, however, this remains to be in-
vestigated. In humans, CK mutations lead to osteopetrosis,
and evidence for increasedMMP activity in the lack of CK ac-
tivity is found in these patients51,52. Strongly elevated type I
collagen fragments (carboxy-terminal telopeptide of type I
collagen, ICTP), which are MMP generated, are found in
the absence of CK activity, suggesting compensational roles
of MMPs52e54. Recently, Henriksen et al.53, demonstrated
that osteoclasts in the absence of CK activity shifted into
a more MMP catabolic mode which results in more MMP,
and not CK, derived fragments of collagen type I. Thus, inhi-
bition of CK and other cysteine proteases might lead to
altered composition and release of protease generated
fragments of type II collagen, however, these data do not
rule out the possibility of a direct effect of CK on de-activating
members of the MMP family.
The cysteine protease CK was shown to be expressed in
some instances of cartilage pathologies and to be involved
in collagen type II degradation18e21,50. CK is a lysosomal
protease that has a pH optimum at approximately pH
5.520,21,50, although activity has been reported in particular
against aggrecan at neutral pH20. The current experiments
were performed under cell culture conditions, which may
not provide the same pH environment as reported in ad-
vanced stages of cartilage pathologies, such as rheumatoid
arthritis and OA37, which may favor CK activity. However,
CK activity was shown to mediate proteoglycan degradation
at neutral pH20,50, even though the protective effect on pro-
teoglycan degradation by inhibition of CK activity was minor
compared to the strongly attenuated cartilage destruction
observed by inhibition of MMP activity, suggesting that CK
is involved in proteoglycan degradation, albeit to a lesser
extent than MMP activity.
The immunohistochemistry of CK suggested the presence
of both secreted and intracellulary stored (lysosomal) CK,
similar to that previously reported for osteoclasts55,56. Thecurrent culture conditions do not affect intracellular pH in
the lysosomes of chondrocytes, meaning that pH conditions
(5.5) are optimal for the protease CK. Collagen fragments
have previously been shown to be transcytosed and de-
graded inside the cells57. Thus, the current experiments do
not suggest a large intracellular role of CK in the chondro-
cytes for the degradation of collagen type II. The inhibitory ef-
fect of cysteine proteases on proteoglycan degradation
remains to be further investigated with respect to whether
this is a result of intracellular or extracellular activity.
The current experiments relied on many parameters for
examination of the cartilage; gross examination of the carti-
lage explants, biochemical markers, immunohistochemistry
and histology, which all pointed towards MMPs, but not cys-
teine proteases, as the essential proteases in cartilage turn-
over. In particular, the immunohistochemistry performed on
cartilage stimulated with OSM and TNF-a in combination
with E64 showed almost complete proteoglycan loss
(Fig. 7, upper panel) and extensive collagen type II degra-
dation. However, the current investigation has partly been
based on the release of the CTX-II epitope, which we
show is not dependent on CK activity in cartilage, and partly
on quantiﬁcation of the released hydroxyproline, which
showed similar results. Importantly, other cleavage sites in
the collagen type II molecule have been shown to depend
on CK activity18,21,50. Thus, by investigation of other neoe-
pitopes than CTX-II, such as the col2-3/4 epitope58, which
might demonstrate other disease mechanisms than CTX-
II, potential effects of CK inhibition could have been identi-
ﬁed. However, the hydroxyproline measurements, which is
independent of protease generated neoepitopes, did not
suggest major roles of CK in articular collagen type II deg-
radation, as no inhibition was observed.
We used both the cysteine protease inhibitor E64 as well
as the cell membrane permeable pro-inhibitor E64d that has
previously been shown to inhibit proteoglycan release from
IL-1 stimulated bovine nasal septum cartilage59. Only
a small reduction of proteoglycan degradation was found,
albeit not signiﬁcant, when using the inhibitors. Several ex-
perimental parameters may explain these differences, as in-
cubation time, choice of tissue, and cytokines are different.
Buttle et al.59, used bovine nasal septum cartilage stimu-
lated with IL-1 for very short time periods in contrast to
the present studies involving articular cartilage stimulated
with OSM and TNF-a for longer time periods. In line with
this, IL-1 can activate cysteine proteases in nasal septum
cartilage as described by Buttle et al.59, but IL-1 has been
found to be less potent to induce cartilage degradation in ar-
ticular cartilage12,60. The cysteine protease inhibitor, E64,
targets CK and other cysteine proteases such as cathepsin
B and L that might contribute to matrix destruction of artic-
ular cartilage61. Cathepsin B was recently shown to gener-
ate the CTX-II fragment in an in vitro experiment, in contrast
to CK62. However, as we did not detect an effect in the cur-
rent experiments on collagen type II degradation and only to
a lesser extent on proteoglycan degradation, this cross-
reactivity of E64 seems to be of less importance.
Conclusion
We propose this ex vivo articular explants’ culture system
as a valuable tool for the molecular characterization of car-
tilage turnover, due to the high in vivo likeness. Using this
model, we found that cytokine induced activation of the car-
tilage led to MMP and CK expression. Inhibition of MMP ac-
tivity resulted in complete abrogation of collagen type II
746 B. C. Sondergaard et al.: Relative contribution of MMP and cysteine protease activitiesdegradation. In contrast, inhibition of cysteine protease ac-
tivity resulted in an increase rather than a decrease in MMP
generated collagen type II fragments of cartilage degrada-
tion. This model and these results may be valuable when
evaluating possible drugs for cartilage diseases.
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